Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

New innovations designed to simplify NGS workflows Enhances critical variant identification through improved ...

Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed ...

Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...

A growing body of research is pushing cancer science toward a radical shift: detecting and stopping the disease years or even decades before a tumor ever forms. Multiple studies now show that ...

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

India's disease burden is undergoing a structural shift. According to the recent data, non-communicable diseases account for ...

When Ivana Goluza Riddell, from NSW, gave birth to her 'happy and healthy' son, her heart swelled with joy. But during a ...

Abstract: Cancer disease is a major health problem in every country, which places an enormous burden on public healthcare systems. Mobile sequencing of biological samples provides immediate data ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

Cells from cancerous tumors can spread, or metastasize, throughout the body. Researchers have long sought to understand what determines where those cells will go and thrive in order to more ...

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options based on patient needs and prior therapies. This segment focuses on systemic treatment ...